What Is IL-7 (Interleukin-7) and What Does It Do?

Interleukin-7 (IL-7) is a small signaling protein, a cytokine, that acts as one of the immune system’s most important survival signals for T cells. Without it, the body cannot properly build or maintain the population of T cells it needs to fight infections and cancer. IL-7 works by binding to a receptor on developing and mature T cells, triggering internal signals that tell those cells to survive, divide, and mature. Its reach extends further than most people expect, touching everything from bone density to gut health to whether engineered cancer therapies work.

Where IL-7 Comes From

Unlike many immune signals that are pumped out by immune cells themselves, IL-7 is produced mainly by non-immune structural cells. The biggest source is stromal cells in the thymus, the organ behind your breastbone where T cells grow up. But IL-7 production isn’t limited to the thymus. Reporter studies in mice have identified IL-7 activity in the skin, intestine, and lymph nodes as well.¹ In the gut specifically, intestinal epithelial cells and goblet cells produce IL-7, where it helps regulate immune cells embedded in the gut lining.²

This scattered production pattern matters. Rather than broadcasting IL-7 through the bloodstream the way some hormones work, the body delivers it locally, in tissues where immune cells live. The supply is limited enough that immune cells essentially compete for it. That built-in scarcity turns out to be a key feature: it helps the body regulate how many T cells survive at any given time, a concept immunologists call homeostatic control.

How IL-7 Builds T Cells in the Thymus

The thymus is where bone-marrow-derived precursor cells are educated and converted into mature T cells. IL-7 is essential to almost every step of this process. Without IL-7 signaling, survival, proliferation, and differentiation of immature thymocytes are all severely impaired.³ Experiments in mice lacking the IL-7 receptor showed that the early expansion phase of thymocytes, which happens before the cells even begin rearranging the genes for their T cell receptors, depends critically on IL-7.⁴ In practical terms, a person or animal that cannot respond to IL-7 ends up with a profoundly small T cell population, which is exactly what happens in certain severe combined immunodeficiencies caused by mutations in the IL-7 receptor gene.

This role is conserved across species. Zebrafish carrying loss-of-function mutations in the IL-7 receptor gene show dramatically reduced thymus cellularity, and the genetic interactions between IL-7 receptor components in zebrafish mirror what researchers see in mammals.⁵ The fact that vertebrates separated by hundreds of millions of years of evolution still depend on the same pathway underscores how fundamental IL-7 is to building a functional adaptive immune system.

Keeping T Cells Alive After They Leave the Thymus

Building T cells is only half the job. Once mature naive T cells exit the thymus and circulate through the body, they still need IL-7 to stay alive. Naive T cells are maintained by a combination of IL-7 and low-level contact with molecules on other cells; together these signals sustain production of anti-death proteins that keep the cells in a resting but viable state.⁶ When researchers removed IL-7 from the equation in mice, both naive CD4 and CD8 T cells failed to survive, and homeostatic expansion in animals with low lymphocyte counts was blocked.⁷

Memory T cells, the subset that provides long-term protection after an infection or vaccination, also rely on IL-7 for their persistence. IL-7 is considered integral to the generation and maintenance of CD8 T cell memory, and insufficient IL-7 is believed to limit survival of these long-lived cells.⁸ The picture is a bit more nuanced than “no IL-7, no memory,” since some resident memory T cells in tissues can persist even after losing their IL-7 receptor, but broadly, IL-7 remains a major driver of how long immune memory lasts.

How IL-7 Signals Inside the Cell

When IL-7 binds its receptor on a T cell, the receptor undergoes a physical rearrangement. The two receptor chains rotate roughly 90 degrees relative to the cell surface, and their internal tails swing close together, going from about 110 ångströms apart to less than 30.⁹ This physical change activates enzymes called JAKs that are attached to the receptor’s inner tails. The JAKs in turn activate a protein called STAT5, which travels to the nucleus and switches on genes that promote cell survival. Studies in human T cells show that STAT5 becomes activated within 15 minutes of IL-7 exposure, and that the anti-death protein Bcl-2 is one of the key downstream targets.¹⁰

The system also has a built-in brake. After IL-7 triggers signaling, the receptor itself gets pulled off the cell surface through a process involving tiny protein-coated pits in the membrane, then chewed up inside the cell. IL-7 also suppresses the gene that encodes its own receptor.¹¹ This double negative-feedback loop means that a T cell that just received a strong IL-7 signal temporarily becomes less sensitive to the next dose. The effect redistributes the limited IL-7 supply more evenly across the T cell population, preventing any one clone from hogging all the survival signal.

The B Cell Question

For decades, immunology textbooks made a clean distinction: IL-7 is absolutely required for B cell development in mice, but humans with IL-7 receptor mutations still produce circulating B cells, so human B cells must not need it. Experiments in the 1990s seemed to confirm this, showing that adding or blocking IL-7 in human bone marrow cultures did not change the rate or character of B cell development.¹²

A 2023 study in Blood challenged that long-standing view. Using bone marrow samples from healthy people and from patients lacking a functional IL-7 receptor, combined with single-cell gene-expression analysis, researchers found that IL-7 signaling does play a meaningful role in human B cell development: it promotes the commitment of early progenitors to the B cell lineage and expands early B cell progenitors.¹³ The reason patients without the receptor still have B cells is not that IL-7 is irrelevant to human B lymphopoiesis, but that the dependency is less absolute than in mice. Human B cell development can limp along without IL-7, but it does so at a deficit. The difference between mice and humans is one of degree, not of kind, and it means the old textbook statement needs updating.

IL-7 Beyond Immune Cells

In the Gut

The gut lining produces its own IL-7, and this locally made cytokine does more than just support immune cells in the intestinal wall. Research in mice has shown that IL-7 also regulates the turnover of the intestinal epithelial cells themselves. In animals lacking T cells, IL-7-producing epithelial cells accumulate and the gut lining overgrows, a condition that reverses when T cells are reintroduced because the T cells consume the excess IL-7. Blocking IL-7 signaling in these T-cell-deficient mice prevented the overgrowth but made the animals more vulnerable to chemical-induced gut damage and colitis.¹⁴ So IL-7 sits at the center of a balancing act: enough to protect the gut lining, but not so much that epithelial cells overproliferate. T cells serve as the thermostat.

In Bone

One of IL-7’s more surprising roles involves bone metabolism. After estrogen levels drop, as happens after menopause or surgical removal of the ovaries, IL-7 production increases. Neutralizing IL-7 in ovariectomized mice prevented the bone loss that normally follows estrogen withdrawal, and the protection came from two directions: blocking IL-7 slowed bone breakdown and simultaneously allowed more new bone to form.¹⁵ The mechanism involves IL-7 stimulating T cells to produce signals that activate osteoclasts, the cells that dissolve bone, while at the same time suppressing osteoblasts, the cells that build bone.¹⁶ Mice lacking the IL-7 receptor actually develop thicker-than-normal trabecular bone.¹⁷ This link between the immune system and bone, sometimes called osteoimmunology, means that conditions with chronically elevated IL-7 could contribute to skeletal fragility.

When IL-7 Drives Disease

Because IL-7 is so good at keeping immune cells alive, it can become a problem when those cells are the wrong ones. In autoimmune diseases, elevated IL-7 or its receptor has been linked to persistence of the very immune cells attacking the body’s own tissues. In rheumatoid arthritis, high IL-7 levels promote the survival of memory T cells that drive joint inflammation. In systemic lupus, a soluble form of the IL-7 receptor circulates at levels that track with disease activity, and IL-7 supports autoreactive T cells and pro-inflammatory cytokine production. In multiple sclerosis, genetic variants in the IL-7 receptor gene are themselves a risk factor for developing the disease.¹⁸

IL-7 also plays a role in certain blood cancers. In T cell acute lymphoblastic leukemia, excessive IL-7/IL-7 receptor signaling can drive leukemia development, speed disease progression, and contribute to resistance against chemotherapy. In this context, the same pathways that keep healthy T cells alive, including STAT5 and PI3K/Akt/mTOR, are hijacked by cancerous cells to fuel their own growth.¹⁹ This dual nature, essential for health but dangerous in excess, makes IL-7 a tricky therapeutic target. Turning it up helps patients who need more T cells; turning it up too far risks feeding the wrong cells.

IL-7 as a Drug

Given that IL-7 is the body’s main T-cell-expanding signal, researchers have been testing lab-made versions of it as a therapy for people whose T cell counts are dangerously low. The most studied population is HIV-infected individuals on antiretroviral therapy who still fail to rebuild their CD4 T cell counts. In a phase I/IIa trial, three weekly injections of recombinant IL-7 produced rapid CD4 increases averaging about 323 cells per microliter at 12 weeks, with gains lasting up to a year. The expanded cells were mostly naive and central memory T cells, and IL-7 appeared to boost thymic output and improve the diversity of the T cell receptor repertoire.²⁰ In dose-finding work, patients receiving a higher dose saw a median gain of about 576 CD4 cells per microliter, more than tripling their baseline count.²¹

Repeated cycles of IL-7 therapy have also been tested. Two phase II trials showed that multiple rounds of injections were well tolerated and achieved sustained CD4 counts above 500 cells per microliter in most participants.²² The clinical interest extends beyond HIV. Sepsis, bone marrow transplant recovery, and idiopathic CD4 lymphopenia are all settings where IL-7 could theoretically help rebuild a depleted immune system.

The HIV Reservoir Complication

There is a catch to using IL-7 in people living with HIV. While the cytokine reliably expands CD4 T cells, it also expands the cells harboring dormant HIV DNA, the so-called viral reservoir. In virally suppressed patients receiving IL-7, memory CD4 T cells proliferated rapidly, which led to a roughly 70 percent increase in the number of circulating cells carrying integrated HIV DNA within four weeks. Genetic diversity of the reservoir also spiked temporarily.²³ Separately, research has shown that in people with low CD4 counts and higher rates of IL-7-driven homeostatic proliferation, proviral DNA is preferentially detected in a specific memory T cell subset, suggesting that IL-7-mediated cell division is one of the mechanisms that keeps the reservoir intact long-term.²⁴

This creates a genuine dilemma for clinicians. IL-7 is among the best tools available for restoring CD4 counts, but it simultaneously strengthens the barrier to curing HIV. Researchers have concluded that IL-7 on its own is not a suitable strategy for eradicating the virus, though it remains useful when the primary goal is immune restoration rather than reservoir reduction.

Boosting Engineered Immune Therapies

A newer and rapidly growing area of IL-7 research sits at the intersection of cancer immunotherapy and synthetic biology. CAR T cells, engineered immune cells designed to target tumors, often lose steam after infusion because they stop proliferating or die off before the tumor is fully eliminated. Researchers have explored IL-7 as a way to keep them going. A long-acting form of IL-7 fused to a protein fragment that extends its half-life promoted the proliferation, persistence, and tumor-killing ability of CAR T cells in mouse models, leading to long-term tumor-free survival in some animals.²⁵

Another approach skips the external drug entirely. Instead of giving IL-7 alongside CAR T cells, some groups have engineered the CAR T cells themselves to secrete IL-7. In one design, an anti-CD19 CAR construct was built with a built-in IL-7 gene, and the resulting cells achieved high transduction rates and showed enhanced persistence in vivo.²⁶ Self-supplying CAR T cells are an appealing concept because they concentrate the survival signal right where it is needed, in the tumor microenvironment, rather than flooding the whole body with a cytokine that could also feed unwanted cell populations. These approaches are still preclinical, but they reflect how central IL-7 has become to thinking about next-generation cell therapies.

IL-7 and the Aging Immune System

As people age, the thymus shrinks, T cell production declines, and the immune system gradually weakens, a process called immunosenescence. IL-7 sits near the center of this decline. With thymic involution, the stromal cells that produce the bulk of IL-7 dwindle, and the remaining T cell pool becomes less diverse and more reliant on homeostatic signals to survive. Research supports a critical role for IL-7 in maintaining what immunologists call a vigorous healthspan, and disruptions to IL-7 signaling are considered a contributor to age-related immune dysfunction.²⁷

Paradoxically, circulating IL-7 levels often rise in older adults. This is not a sign of abundance but of underuse: when there are fewer T cells around to consume IL-7, more of it accumulates in the blood. Elevated serum IL-7 in an elderly person may actually signal that their T cell compartment is depleted rather than well-supplied. This counterintuitive relationship is important to grasp because it means a blood test showing “high IL-7” in an older adult is not reassuring; it is a marker of the problem, not a sign of compensation working correctly.

IL-7 Signaling Gone Wrong in HIV

Beyond the reservoir issue, HIV infection itself disrupts the normal IL-7 signaling machinery in T cells. In people with active virus replication, the JAK/STAT5 pathway that IL-7 depends on becomes chronically activated at a low level even without IL-7 present, and the cells’ ability to respond properly to IL-7 is blunted. Functional downstream responses, including the upregulation of the survival protein Bcl-2, are impaired in CD4 T cells from patients with detectable virus.²⁸ So HIV attacks IL-7 biology from two angles: it depletes the T cells that need IL-7, and it damages the signaling machinery inside the surviving cells so they respond poorly to whatever IL-7 is available. This double hit helps explain why CD4 T cell recovery can be so sluggish even after viral suppression is achieved with antiretroviral drugs.